Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Danny Tomka
Angiotech PharmaceuticalsANP.TODON'T BUYMar 29, 2005
Boston Scientific (BSX-N) had the majority share in the business, they are a supplier, so why is it weak. Boston is just as weak. The problem with the pharma sector is investors never look at what it is today but what is the marginal change tomorrow, such as competition with a better product.
$17.64
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
COMMENT
The stock has been hurt, but it is more of an issue because of stents. Sales projections are falling off. At this stage, you are probably facing tax loss selling for the rest of the month and then get a January bounce if the company has a decent outlook going forward. Competition has increased in this area.
biotechnologypharmaceutical
BUY
The worst news is already in the stock. At these levels, it's a Buy. Have product pipeline starting to develop. Looking at drug eluding stents in the Japanese market.
John ZechnerOwned
biotechnologypharmaceutical
DON'T BUY
Had a long-term problem with stents. Made a series of acquisitions which all look very interesting. Not sure what the effect of this will be. A raving buy at this price, but does not like buying a stock on the way down.
Chyanne FickesOwned
biotechnologypharmaceutical
